Sam Brusco, Associate Editor06.09.22
Thermo Fisher Scientific has earned U.S. Food and Drug Administration (FDA) clearance for its EliA RNA Pol III and EliA Rib-P tests to help diagnose Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).
The EliA portfolio now offers a more comprehensive menu of automated connective tissue tests.
“Autoimmune diseases can be a challenge to diagnose. Reliable and accurate laboratory tests that provide clinical clarity are essential tools for clinicians managing these patients,” Dr. Henry Homburger, Professor Emeritus of Laboratory Medicine at Mayo Clinic College of Medicine, and laboratory director, Thermo Fisher Phadia Immunology Reference Laboratory, told the press. “The addition of RNA Polymerase III and Ribosomal P to the EliA connective tissue disease test menu will add considerable value to the diagnosis of SSc and SLE.”
The EliA RNA Pol III test completes a criteria-based EliA SSc panel and is the first fully automated RNA Polymerase test available in the U.S.
“The availability of a strong CTD test menu on a fully automated instrument could improve the efficiency and productivity of diagnostic laboratories,” added Homburger. “The new EliA RNA Pol III and EliA Rib-P tests have been designed to improve the differentiation of SSc and SLE from other connective tissue diseases. Targeting existing diagnostic care gaps can potentially lead to earlier and more accurate diagnosis and ultimately improve clinical outcomes for patients.”
The EliA portfolio now offers a more comprehensive menu of automated connective tissue tests.
“Autoimmune diseases can be a challenge to diagnose. Reliable and accurate laboratory tests that provide clinical clarity are essential tools for clinicians managing these patients,” Dr. Henry Homburger, Professor Emeritus of Laboratory Medicine at Mayo Clinic College of Medicine, and laboratory director, Thermo Fisher Phadia Immunology Reference Laboratory, told the press. “The addition of RNA Polymerase III and Ribosomal P to the EliA connective tissue disease test menu will add considerable value to the diagnosis of SSc and SLE.”
The EliA RNA Pol III test completes a criteria-based EliA SSc panel and is the first fully automated RNA Polymerase test available in the U.S.
“The availability of a strong CTD test menu on a fully automated instrument could improve the efficiency and productivity of diagnostic laboratories,” added Homburger. “The new EliA RNA Pol III and EliA Rib-P tests have been designed to improve the differentiation of SSc and SLE from other connective tissue diseases. Targeting existing diagnostic care gaps can potentially lead to earlier and more accurate diagnosis and ultimately improve clinical outcomes for patients.”